Insulet (PODD) Down 8.2% Since Last Earnings Report: Can It Rebound?

Core Insights - Insulet Corporation reported strong fourth-quarter earnings and revenue growth, with adjusted earnings per share of $1.55, up 34.8% year-over-year, surpassing estimates by 4.87% [3] - The company’s revenues for Q4 reached $783.8 million, exceeding estimates by 2.15% and reflecting a year-over-year increase of 31.2% [4] Financial Performance - Insulet's full-year 2025 earnings per share were $4.97, a 53.4% increase from the previous year, also surpassing estimates by 1.2% [3] - The gross profit for Q4 was $568.6 million, up 31.9% year-over-year, with a gross margin of 72.5%, expanding by 32 basis points [6] - Operating profit for the quarter was $146.3 million, reflecting a 33.7% increase year-over-year, with an operating margin of 18.7%, up 36 basis points [7] Revenue Breakdown - Total Omnipod revenues for Q4 were $781.8 million, a 33.5% increase year-over-year, with international revenues rising 50.7% [5] - The Drug Delivery business reported revenues of $2 million, down 83.4% year-over-year [5] Cash Position - Insulet ended Q4 2025 with cash and cash equivalents of $716.1 million, down from $953.4 million at the end of 2024, but cumulative net cash from operating activities increased to $569.3 million from $430.2 million year-over-year [8] Future Outlook - For full-year 2026, Insulet projects total revenue growth of 20%-22% at constant exchange rates, with Omnipod revenue growth expected at 21%-23% [10] - The company anticipates a decline of approximately 50% in Drug Delivery revenues at constant exchange rates [10] - For Q1 2026, revenue growth is projected at 25%-27%, with Omnipod revenues expected to rise 28%-30% [11] Market Position - Insulet has a strong Growth Score of A, but a B on the Momentum Score, indicating mixed performance in different investment strategies [13] - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [14]